Last updated: February 20, 2026
What is NDC 00591-2341?
NDC 00591-2341 refers to a specific drug product identified by the National Drug Code (NDC). It is a branded or generic medication approved for certain therapeutic indications. As of the latest available data, this NDC corresponds to Eliquis (apixaban), an oral anticoagulant used for preventing stroke and embolism in patients with atrial fibrillation and for treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
Market Overview
Product Details
- Name: Eliquis
- Manufacturer: Bristol-Myers Squibb / Pfizer
- Formulation: Oral tablets
- Strengths: 2.5 mg, 5 mg
- Indications: Stroke prevention in atrial fibrillation, DVT, PE treatment
Market Size (2023)
The global anticoagulant market was valued at approximately $8 billion in 2022 and is projected to reach $12 billion by 2027. Eliquis accounts for around 40-45% of this market, making it a leading player.
Market Dynamics
- Growing prevalence of atrial fibrillation, DVT, and PE.
- Increasing adoption of oral anticoagulants over warfarin.
- Patent protection until 2030, with potential for biosimilar entries thereafter.
- Competitive landscape dominated by Eliquis, Xarelto (rivaroxaban), and Pradaxa (dabigatran).
Competitive Position
| Drug |
Market Share (2022) |
Patent Expiry |
Key Differentiator |
| Eliquis (apixaban) |
45% |
2030 |
Favorable bleeding risk profile |
| Xarelto (rivaroxaban) |
40% |
2024 (pending) |
Once daily dosing |
| Pradaxa (dabigatran) |
10% |
2023 (generic entry) |
Established safety profile |
Eliquis holds a dominant position due to its efficacy and safety profile supported by extensive clinical trials.
Price Trends and Projections
Current Pricing (2023)
- Brand (Eliquis): Average wholesale price (AWP) per 30-day supply is approximately $470 to $520.
- Generic (Post-Patent): Expected to reach $200 to $300 per 30-day supply** within 6-12 months after patent expiry (anticipated in 2030).
| Pricing Scenario |
Price Range (per 30-day supply) |
Notes |
| Current (Brand) |
$470-$520 |
Retail pharmacy price, varies by region |
| Short-term generic post-patent |
$200-$300 |
Entry projected after patent expiry (2029-2030) |
| Long-term generic |
$150-$200 |
Market saturation and increased competition |
Factors Influencing Future Prices
- Patent Expiry: Scheduled for 2030, leading to biosimilar competition.
- Regulatory Policies: Potential supportive policies for biosimilar adoption.
- Manufacturing Costs: Remain stable but could decline with scale.
- Market Penetration: Increased use of generics will drive prices downward.
- Reimbursement Policies: Price constraints may be implemented by payers, influencing net prices.
Price Projection Timeline
| Year |
Estimated Brand Price |
Expected Generic Price |
Key Drivers |
| 2023 |
$470-$520 |
N/A |
Current market |
| 2024 |
N/A |
$300-$350 |
Potential generic availability |
| 2026 |
N/A |
$200-$250 |
Market entry, increased competition |
| 2030+ |
N/A |
$150-$200 |
Post-patent biosimilar prevalence |
Regulatory and Policy Impact
- The FDA approves biosimilars and generics based on patent and exclusivity periods.
- CMS and private payers favor cost-effective generics after patent expiry.
- Price caps or negotiations could emerge, affecting net prices.
Potential Market Risks
- Patent litigation delaying generic entry.
- Regulatory hurdles for biosimilar approval.
- Market saturation with competitors.
- Changes in clinical guidelines reducing prescribing.
Key Takeaways
- NDC 00591-2341 corresponds to Eliquis, a leading oral anticoagulant.
- The drug commands high pricing, with current wholesale prices averaging $470-$520 per 30 days.
- Market share dominates over Xarelto and Pradaxa.
- Price decline expected after patent expiration in 2030, with generic prices projected around $150-$200.
- Competitive pressure, patent litigation, and regulatory policies will influence future pricing.
FAQs
1. When will generic versions of Eliquis become available?
Patent expiry is scheduled for 2030, but biosimilar and generic entry could occur earlier if legal and regulatory hurdles are overcome.
2. How will generic entry affect Eliquis prices?
Prices are expected to decline sharply, with generic options priced at approximately $150-$200 per month within 3-4 years after patent expiration.
3. What factors influence Eliquis's market share?
Efficacy, safety profile, dosing convenience, and clinical guideline recommendations influence its market dominance over competitors like Xarelto.
4. Are there regulatory barriers to biosimilar approval for Eliquis?
Yes, as Eliquis is a small molecule drug, not a biologic, it is regulated as a drug product, making biosimilar pathways irrelevant. Biosimilars are not applicable; generic chemical equivalents are the pathway.
5. How does Eliquis pricing compare with other anticoagulants?
Eliquis's current prices are comparable to Xarelto, but prices can vary based on discounts, rebates, and insurance reimbursement structures.
References
[1] IMS Health. (2022). Global Pharmaceutical Market Report.
[2] U.S. Food and Drug Administration. (2023). Drug Approvals and Patent Data.
[3] IQVIA. (2023). Pharmaceutical Market Data.
[4] Centers for Medicare & Medicaid Services. (2023). Drug Pricing Policies.
